INGN · Inogen Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $85.11M | - | $92.39M | $92.28M | $82.28M | - | $88.83M | $88.77M | $78.03M | - |
| Cost of Revenue | $47.25M | - | $51.07M | $50.94M | $45.91M | - | $47.49M | $46.03M | $43.65M | - |
| Gross Profit | $37.86M | - | $41.32M | $41.34M | $36.37M | - | $41.34M | $42.74M | $34.37M | - |
| R&D | $5.10M | - | $4.84M | $5.21M | $4.03M | - | $3.52M | $5.62M | $6.58M | - |
| SG&A | $17.50M | - | $18.15M | $16.87M | $16.24M | - | $19.26M | $18.57M | $17.13M | - |
| Total Operating Expenses | $47.20M | - | $48.43M | $47.47M | $44.03M | - | $49.14M | $49.80M | $50.65M | - |
| D&A | $4.90M | - | $3.93M | $4.01M | $5.19M | - | $4.21M | $4.16M | $5.26M | - |
| Operating Income | ($9.34M) | - | ($7.12M) | ($6.13M) | ($7.66M) | - | ($7.79M) | ($7.06M) | ($16.27M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | ($174.0K) | - | ($146.0K) | ($153.0K) | ($97.0K) | - | ($101.0K) | ($7.0K) | ($150.0K) | - |
| Net Income | ($8.32M) | - | ($5.29M) | ($4.15M) | ($6.17M) | - | ($5.96M) | ($5.59M) | ($14.58M) | - |
| EPS - Basic | ($0.30) | - | ($0.20) | ($0.15) | ($0.25) | - | ($0.25) | ($0.24) | ($0.62) | - |
| EPS - Diluted | ($0.30) | - | ($0.20) | ($0.15) | ($0.25) | - | ($0.25) | ($0.24) | ($0.62) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $93.11M | $103.73M | $106.48M | $103.69M | $118.89M | $113.80M | $105.69M | $97.92M | $107.44M | $125.49M |
| Accounts Receivable | $41.87M | $38.86M | $40.37M | $38.59M | $36.62M | $29.56M | $34.23M | $36.04M | $40.22M | $42.24M |
| Inventory | $24.99M | $25.97M | $25.07M | $24.31M | $26.27M | $24.81M | $23.32M | $24.05M | $24.60M | $21.84M |
| Accounts Payable | $24.09M | $20.26M | $21.22M | $21.90M | $23.26M | $16.62M | $15.46M | $14.99M | $15.92M | $13.45M |
| Current Assets | $190.66M | $198.30M | $203.72M | $203.12M | $200.71M | $185.45M | $192.55M | $194.79M | $199.19M | $207.07M |
| Total Assets | $285.93M | $298.63M | $307.01M | $312.04M | $308.41M | $296.19M | $306.17M | $308.92M | $315.60M | $326.19M |
| Current Liabilities | $61.45M | $63.53M | $64.94M | $67.07M | $65.45M | $76.69M | $72.40M | $72.19M | $73.91M | $72.50M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $103.02M | $106.39M | $109.83M | $112.55M | $110.46M | $122.33M | $120.77M | $121.32M | $123.70M | $121.38M |
| Stockholders' Equity | $182.91M | $192.23M | $197.18M | $199.49M | $197.95M | $173.86M | $185.40M | $187.59M | $191.90M | $204.81M |
| Retained Earnings | ($183.91M) | ($175.58M) | ($168.46M) | ($163.16M) | ($159.01M) | ($152.84M) | ($143.08M) | ($137.12M) | ($131.53M) | ($116.95M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($6.68M) | - | - | - | ($16.79M) | - | - | - | ($4.75M) | - |
| Investing Cash Flow | ($1.98M) | - | - | - | ($2.04M) | - | - | - | ($13.44M) | - |
| Financing Cash Flow | ($2.12M) | - | - | - | $23.95M | - | - | - | $285.0K | - |
| CapEx | $210.0K | - | - | - | $292.0K | - | - | - | $1.31M | - |
| Free Cash Flow | ($6.89M) | - | - | - | ($17.08M) | - | - | - | ($6.06M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 44.5% | - | 44.7% | 44.8% | 44.2% | - | 46.5% | 48.1% | 44.1% | - |
| Operating margin | -11.0% | - | -7.7% | -6.6% | -9.3% | - | -8.8% | -8.0% | -20.9% | - |
| EBITDA margin | -5.2% | - | -3.4% | -2.3% | -3.0% | - | -4.0% | -3.3% | -14.1% | - |
| Net margin | -9.8% | - | -5.7% | -4.5% | -7.5% | - | -6.7% | -6.3% | -18.7% | - |
| Free cash flow margin | -8.1% | - | - | - | -20.8% | - | - | - | -7.8% | - |
| FCF / Net income | 0.83 | - | - | - | 2.77 | - | - | - | 0.42 | - |
| R&D / Revenue | 6.0% | - | 5.2% | 5.6% | 4.9% | - | 4.0% | 6.3% | 8.4% | - |
| SG&A / Revenue | 20.6% | - | 19.6% | 18.3% | 19.7% | - | 21.7% | 20.9% | 22.0% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -2.9% | - | -1.7% | -1.3% | -2.0% | - | -1.9% | -1.8% | -4.6% | - |
| Return on equity | -4.6% | - | -2.7% | -2.1% | -3.1% | - | -3.2% | -3.0% | -7.6% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.10 | 3.12 | 3.14 | 3.03 | 3.07 | 2.42 | 2.66 | 2.70 | 2.70 | 2.86 |
| Quick ratio | 2.70 | 2.71 | 2.75 | 2.67 | 2.67 | 2.09 | 2.34 | 2.37 | 2.36 | 2.55 |
| Cash ratio | 1.52 | 1.63 | 1.64 | 1.55 | 1.82 | 1.48 | 1.46 | 1.36 | 1.45 | 1.73 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.56 | 1.55 | 1.56 | 1.56 | 1.56 | 1.70 | 1.65 | 1.65 | 1.64 | 1.59 |
| Liabilities / Assets | 0.36 | 0.36 | 0.36 | 0.36 | 0.36 | 0.41 | 0.39 | 0.39 | 0.39 | 0.37 |
| Efficiency | ||||||||||
| Asset turnover | 0.30 | - | 0.30 | 0.30 | 0.27 | - | 0.29 | 0.29 | 0.25 | - |
| Inventory turnover | 1.89 | - | 2.04 | 2.10 | 1.75 | - | 2.04 | 1.91 | 1.77 | - |
| Days sales outstanding | 180d | - | 160d | 153d | 162d | - | 141d | 148d | 188d | - |
| Days inventory outstanding | 193d | - | 179d | 174d | 209d | - | 179d | 191d | 206d | - |
| Days payable outstanding | 186d | - | 152d | 157d | 185d | - | 119d | 119d | 133d | - |
| Cash conversion cycle | 187d | - | 187d | 170d | 186d | - | 201d | 220d | 261d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 0.9x | - | 1.1x | 1.0x | 0.9x | - | 1.2x | 1.0x | 1.0x | - |
| P / S | 2.0x | - | 2.4x | 2.1x | 2.2x | - | 2.6x | 2.2x | 2.4x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 3.4% | - | 4.0% | 4.0% | 5.5% | - | 5.8% | 6.1% | 8.1% | - |
| Revenue CAGR (3y) | 5.7% | - | -4.3% | -3.7% | 0.8% | - | -1.6% | -4.4% | -3.5% | - |
| Revenue CAGR (5y) | -0.4% | - | 4.4% | 5.2% | -1.4% | - | -0.6% | -2.6% | -2.9% | - |
| Gross profit growth (YoY) | 4.1% | - | -0.1% | -3.3% | 5.8% | - | 22.4% | 25.5% | 11.8% | - |
| Operating income growth (YoY) | -21.9% | - | 8.7% | 13.2% | 53.0% | - | 83.3% | 40.0% | 25.7% | - |
| Net income growth (YoY) | -34.8% | - | 11.2% | 25.7% | 57.6% | - | 87.0% | 43.1% | 28.4% | - |
| EPS growth (YoY) | -20.0% | - | 20.0% | 37.5% | 59.7% | - | 87.3% | 42.9% | 29.5% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 59.6% | - | - | - | -181.9% | - | - | - | 17.9% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -7.6% | 10.6% | 6.3% | 6.3% | 3.2% | -15.1% | -19.6% | -31.7% | -31.8% | -31.1% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Geographic
$295.30M totalUS$156.48M · 53.0%
Non Us$138.83M · 47.0%
Peer comparison
Same SIC group: Orthopedic, Prosthetic & Surgical Appliances & Supplies
Comparing Inogen Inc against the 5 most active filers in the same SIC group.